Listed by the USPTO as KELLY, ROBERT M
Tech Center 1700 • Art Units: 1631 1633 1638 1651 1654 1656 1759
This examiner grants 74% of resolved cases
KELLY, ROBERT M is a USPTO patent examiner in tech center 1700 and art unit 1631. The record contains 947 resolved cases, an allowance rate of 74.1%, and a median of 1058 days to allowance. The interview lift is 24.1%, showing that direct examiner contact can be a meaningful part of prosecution practice in this docket.
Figene LLC, Krystal Biotech Inc., and ModernaTX Inc. are the leading companies. The leading firms are NORTON ROSE FULBRIGHT US LLP, MARSHALL, GERSTEIN & BORUN LLP, and BANNER & WITCOFF, LTD. Practitioners should combine technically detailed written responses with focused interviews, while using the allowance and timing figures to set expectations for claim development and prosecution duration.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18672502 | TERMINALLY MODIFIED RNA | Non-Final OA | ModernaTX, Inc. |
| 18342642 | METHODS OF TREATING LYSOSOMAL DISORDERS | Final Rejection | The Regents of the University of California |
| 18467826 | PHARMACEUTICAL COMPOSITION FOR TREATING NON-ALCOHOLIC FATTY LIVER, NON-ALCOHOLIC STEATOHEPATITIS, OR HEPATIC FIBROSIS USING SSU72 PROTEIN OR A POLYNUCLEOTIDE ENCODING THE SAME | Final Rejection | RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY |
| 19147007 | COMPOSITIONS COMPRISING SUPRAMOLECULAR ASSEMBLIES OF PEPTIDE AMPHIPHILES AND ORGANIC CATIONS AND METHODS OF USE THEREOF | Non-Final OA | Northwestern University |
| 17767856 | ONCOLYTIC VIRUSES THAT EXPRESS MULTI-SPECIFIC IMMUNE CELL ENGAGERS | Final Rejection | Arizona Board of Regents on Behalf of Arizona State University |
| 18511568 | DYSTROPHIN CONSTRUCTS CONTAINING R11-R12 | Non-Final OA | THE CURATORS OF THE UNIVERSITY OF MISSOURI |
| 18703201 | METHODS OF USE AND ADMINISTRATION OF ENCAPSULATED CELLS | Non-Final OA | William Marsh Rice University |
| 18581682 | Adeno-Associated-Virus Rep Sequences, Vectors and Viruses | Non-Final OA | The Research Foundation for the State University of New York |
| 18872451 | A Cell Surface Marker Signature for Arrhythmogenic Pluripotent Stem Cell-Derived Cardiomyocytes | Non-Final OA | The University of Queensland |
| 18545176 | Combination Treatment | Non-Final OA | Duke University |
| 18018552 | UNIVERSAL ANTIGEN-SPECIFIC T CELL BANKS AND METHODS OF MAKING AND USING THE SAME THERAPEUTICALLY | Final Rejection | Baylor College of Medicine |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy74.1% of resolved applications examined by Robert M Kelly were allowed (947 resolved cases), compared with 28.4% across Art Unit 1631 over the last five years.
This examiner's interview lift is +24.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Robert M Kelly took 1,058 days on average from filing to allowance.
Robert M Kelly examines applications in Art Unit 1631 in Tech Center 1700 (Chemistry & Materials).
